EXPERIMENTAL AND CLINICAL EPILEPTOLOGY
Abstract
This article reviews the issues of experimental and clinical epileptology. For the development and implementation of new medications and technologies of medicinal interventions, as well as investigation of main “targets” for anti-epileptic drugs, it is necessary to develop the experimental models of various forms of epilepsy and epileptic seizures. To this end, we studied the alterations of cerebral electrical activity in rats with chronic cobalt epileptogenic focus which represents an optimal experimental model of epileptic state. The significance of hypothalamus was shown to be the lead (determinate) structure within the pathologic epileptic system during formation of secondary generalized seizures. The drug” targets” and possibilities for combined administration of anticonvulsants and antioxidants have been revealed. Pharmaco-genetic investigations enable us to predict the effects of different antiepileptic drugs.
About the Authors
G. N. Avakyan
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
O. L. Badalyan
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
S. G. Burd
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
Е. А. Valdman
GU scientific research institute of pharmacology named after V.V. Zakusov of RAMS
Russian Federation
Russian Federation
Т. А. Voronina
GU scientific research institute of pharmacology named after V.V. Zakusov of RAMS
Russian Federation
Russian Federation
L. N. Nerobkova
GU scientific research institute of pharmacology named after V.V. Zakusov of RAMS
Russian Federation
Russian Federation
Е. V. Krikova
GU scientific research institute of pharmacology named after V.V. Zakusov of RAMS
Russian Federation
Russian Federation
G. G. Аvakyan
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
A. S. Chukanova
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
M. I. Stoyko
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
А. А. Savenkov
GOU VPO “Russian state medical university named after N.I. Pirogov” of Roszdrav
Russian Federation
Russian Federation
References
1. Аксенова М. Г., Бурд С. Г., Авакян Г. Н. и др. Ассоциация полиморфизма С802Т гена глюкуронозилтрансферазы с эффективной дозой топирамата// Журнал неврологии и психиатрии им.С.С.Корсакова: научно-практический рецензируемый журнал — 2007. — Том 107,N 5 . — С. 63-64.
2. Аксенова М. Г., Качалин Е. Ю., Бурд С. Г., Авакян Г. Н., Бадалян О. Л., Савенков А. А., Тертышник О. Ю., Дорофеева М. Ю., Белоусова Е. Д., Гусев Е. И. Связь полиморфизма C3435T гена MDR1 с эффективностью действия карбамазепинов.// Медицинская Генетика, 6/2007, сс. 39-41.
3. Вальдман Е.А. Проблемы внедрения достижений фармакогеномики. Журнал «Ремедиум», № 3-2008
4. Карлов В.А. Детская эпилепсия как инструмент познания развивающегося мозга.// Журнал неврологии и психиатрии им.С.С.Корсакова – 2002, №5, с. 4-5.
5. Крикова Е.В, Вальдман Е.А, Авакян Г.Н., Андреев Я.А., Денисов Е.В, Ридер Ф.К., Биктимеров Р.Р., Чуканова А.С., Бурд С.Г Изучение ассоциации полиморфизма гена SCN1А с эффективной дозой ламотриджина // Журнал неврологии и психиатрии им. С. С. Корсакова: научнопрактический рецензируемый журнал. — 2009; том 10, с. 59-65
6. Раменский В.Е., Сюняев Ш.Р. Вычислительный анализ полиморфизма генома человека Молекулярная биология, 2009; том 43, N 2, с.286-294
7. Середенин С. Б. Лекции по фармакогенетике. 2004; М.: МИА.-303 с
8. Симбирцев А.С., Громова А.Ю., 2005 Полиморфизм генов семейства IL-1 человека Журнал 'Цитокины и воспаление'. 2005; № 2
9. Arzimanoglou A, Hirsch E, Nehlig A, Castelnau P, Gressens P, Pereira de Vasconcelos A. Epilepsy and neuroprotection: an illustrated review. Epileptic Disord. 2002; Sep;4(3):173-82
10. Evans WE, Johnson JA Pharmacogenomics: the inherited basis for interindividual differences in drug response Annu Rev Genomics Hum Genet. 2001;2:9-39
11. Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am J Med. 2007; Apr;120(4 Suppl 1):S21-5.
12. Guillouzo A, Guguen-Guillouzo C. Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin Drug Metab Toxicol. 2008; Oct;4(10):1279-49
13. Ieiri I, Takane H, Hirota T, Otsubo K, Higuchi S. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):651-7414. Johnson JA, Evans WE. Molecular
14. diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol Med. 2002 Jun;8(6):300-5
15. Kalow W. (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. May-Jun;6(3):162-5
16. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A «silent» polymorphism in the MDR1 gene changes substrate specificity. Science. 2007 Jan 26;315(5811):525-8. Epub 2006 Dec 21
17. Kirchheiner J, Fuhr U, Brockmöller J. (2005) Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov. Aug;4(8):639-47
18. Knight A Non-animal methodologies within biomedical research and toxicity testing. ALTEX. 2008;25(3):213-31
19. Lazarowski A, Czornyj L., Lubienicki F, Girardi E, Vazquez S, D’Giano C. (2007) ABA transporters during epilepsy and mechanisms underluing multidrug resistance in refractory epilepsy. Epilepsia 48 Suppl 5:140-149.
20. Lazarowski A, Massaro M, Schteinschnaider A, Intruvini S, Sevlever G, Rabinowicz A. 2004) Neuronal MDR-1 gene expression and persistant low levels of anticonvulsants in a chil with refractory epilepsy.Ther Drug Monit 26:44-46
21. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. (1999) Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1:731-734.
22. Lesko LJ. (2007) Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. Jun;81(6):807-16.
23. Lewis LD. (2005) Personalized drug therapy; the genome, the chip and the physician. Br J lin Pharmacol. Jul;60(1):1-4.
24. Loscher W, Klotz U, Zimprich F, Schmidt D (2008) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, **(*) 1-23
25. Maeda K, Sugiyama Y Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs Drug Metab Pharmacokinet. 2008;23(4):223-35
26. Perucca E. (2001) Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol. Dec;15(6):405-17
27. Phillips KA, Van Bebber SL. (2004) A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. Dec;5(8):1139-49
28. Pirazzoli A, Recchia G. (2004) Pharmacogenetics and pharmacogenomics: are they still promising? Pharmacol Res. Apr;49(4):357-61
29. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, Wieser HG, Pauli-Magnus C. (2007) Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbanazepine and phenytoin disposition. Acta Neurol Scand 115:232-242.
30. Srinivasan BS, Doostzadeh J, Absalan F, Mohandessi S, Jalili R, Bigdeli S, Wang J, Mahadevan J, Lee CL, Davis RW, William Langston J, Ronaghi M. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease. Hum Mutat. 2009 Feb;30(2):228-38.
31. Stefan H., Feuerstein TJ. (2007) Novel anticonvulsant drugs. Pharmacol Ther. Jan;113(1):165-83.
32. Stephen B. Liggett, Pharmacogenetic applications of the Human Genome project Nature Medicine 7, 281 – 283
33. Weber WW. The legacy of pharmacogenetics and potential applicationsMutat Res. 2001 Aug 8;479(1-2):1-18.
34. Wolf P. Historical aspects of idiopathic generalized epilepsies// Epilepsia. – 2005, v.46, suppl. 9, p. 7-9.
Review
For citations:
Avakyan G.N., Badalyan O.L., Burd S.G., Valdman Е.А., Voronina Т.А., Nerobkova L.N., Krikova Е.V., Аvakyan G.G., Chukanova A.S., Stoyko M.I., Savenkov А.А. EXPERIMENTAL AND CLINICAL EPILEPTOLOGY. Epilepsy and paroxysmal conditions. 2010;2(4):41-54. (In Russ.)
Views: 517
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
